Potential drug interactions mediated by renal organic anion transporter OATP4C1

Journal of Pharmacology and Experimental Therapeutics

Volumn 362, Issue 2, 2017, Pages 271-277

  Sato, Toshihiro ^a   Mishima, Eikan ^b   Mano, Nariyasu ^a   Abe, Takaaki ^b,c   Yamaguchi, Hiroaki ^a  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CRIZOTINIB; FLUINDOSTATIN; LEVOFLOXACIN; LIOTHYRONINE; NICARDIPINE; ORGANIC ANION TRANSPORTER H; QUINIDINE; RITONAVIR; SAQUINAVIR; SPIRONOLACTONE; VERAPAMIL; CYTOCHROME P450 3A INHIBITOR; DRUG; ORGANIC ANION TRANSPORTER; SLCO4C1 PROTEIN, HUMAN;

AMINO ACID TRANSPORT; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG SCREENING; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; ANIMAL; DOG; DOSE RESPONSE; DRUG INTERACTION; MDCK CELL LINE; METABOLISM; PHYSIOLOGY;

ANIMALS; CYTOCHROME P-450 CYP3A INHIBITORS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MADIN DARBY CANINE KIDNEY CELLS; ORGANIC ANION TRANSPORTERS; PHARMACEUTICAL PREPARATIONS; RITONAVIR;

EID: 85024485718     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.117.241703     Document Type: Article

References (43)

1. Capucci A, Aschieri D, and Villani GQ (1998) Clinical pharmacology of antiar-rhythmic drugs. Drugs Aging 13:51–70.
2. Chen N and Reith ME (2007) Substrates and inhibitors display different sensitivity to expression level of the dopamine transporter in heterologously expressing cells. J Neurochem 101:377–388.
3. Chioukh R, Noel-Hudson MS, Ribes S, Fournier N, Becquemont L, and Verstuyft C (2014) Proton pump inhibitors inhibit methotrexate transport by renal basolateral organic anion transporter hOAT3. Drug Metab Dispos 42:2041–2048.
4. Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, Dean DC, et al. (2007) Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 321:673–683.
5. Duan P, Li S, Ai N, Hu L, Welsh WJ, and You G (2012) Potent inhibitors of human organic anion transporters 1 and 3 from clinical drug libraries: discovery and molecular characterization. Mol Pharm 9:3340–3346.
6. Center for Drug Evaluation and Research (CDER) (2012) Guidance for Industry: Drug Interaction Studies — Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations U.S. Department of Health and Human Services, Food and Drug Administration, Rockville, MD.
7. Forette F, Bellet M, Henry JF, Hervy MP, Poyard-Salmeron C, Bouchacourt P, and Guerret M (1985) Effect of nicardipine in elderly hypertensive patients. Br J Clin Pharmacol 20 (Suppl 1):125S–129S.
8. Fujiwara Y, Hamada A, Mizugaki H, Aikawa H, Hata T, Horinouchi H, Kanda S, Goto Y, Itahashi K, Nokihara H, et al. (2016) Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism. Cancer Sci 107:1117–1123.
9. Hagenbuch B and Meier PJ (2003) The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609:1–18.
10. Hagenbuch B and Meier PJ (2004) Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653–665.
11. Hsu A, Granneman GR, and Bertz RJ (1998) Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35:275–291.
12. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387–412.
13. Izumi S, Nozaki Y, Maeda K, Komori T, Takenaka O, Kusuhara H, and Sugiyama Y (2015) Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions. Drug Metab Dispos 43:235–247.
14. Krecic-Shepard ME, Barnas CR, Slimko J, Jones MP, and Schwartz JB (2000) Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol 40:219–230.
15. Kullak-Ublick GA, Stieger B, and Meier PJ (2004) Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 126:322–342.
16. Landersdorfer CB, Kirkpatrick CM, Kinzig M, Bulitta JB, Holzgrabe U, Jaehde U, Reiter A, Naber KG, Rodamer M, and Sörgel F (2010) Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid. Br J Clin Pharmacol 69:167–178.
17. Laskin OL, de Miranda P, King DH, Page DA, Longstreth JA, Rocco L, and Lietman PS (1982) Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob Agents Chemother 21:804–807.
18. Lau YY, Huang Y, Frassetto L, and Benet LZ (2007) effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194–204.
19. Lu Y, Nakanishi T, and Tamai I (2013) Functional cooperation of SMCTs and URAT1 for renal reabsorption transport of urate. Drug Metab Pharmacokinet 28:153–158.
20. Małgorzewicz S, Debska-Slizien A, Rutkowski B, and Lysiak-Szydłowska W (2008) Serum concentration of amino acids versus nutritional status in hemodialysis patients. J Ren Nutr 18:239–247.
21. Meijers BK, Bammens B, Verbeke K, and Evenepoel P (2008) A review of albumin binding in CKD. Am J Kidney Dis 51:839–850.
22. Mikkaichi T, Suzuki T, Tanemoto M, Ito S, and Abe T (2004a) The organic anion transporter (OATP) family. Drug Metab Pharmacokinet 19:171–179.
23. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, et al. (2004b) Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci USA 101:3569–3574.
24. Oettl K, Birner-Gruenberger R, Spindelboeck W, Stueger HP, Dorn L, Stadlbauer V, Putz-Bankuti C, Krisper P, Graziadei I, Vogel W, et al. (2013) Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. J Hepatol 59:978–983.
25. Ouellet D, Hsu A, Granneman GR, Carlson G, Cavanaugh J, Guenther H, and Leonard JM (1998) Pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther 64:355–362.
26. Overdiek HW, Hermens WA, and Merkus FW (1985) New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther 38:469–474.
27. Pan X, Wang L, Gründemann D, and Sweet DH (2013) Interaction of Ethambutol with human organic cation transporters of the SLC22 family indicates potential for drug-drug interactions during antituberculosis therapy. Antimicrob Agents Chemother 57:5053–5059.
28. Parvez MM, Kaisar N, Shin HJ, Jung JA, and Shin JG (2016) Inhibitory interaction potential of 22 antituberculosis drugs on organic anion and cation transporters of the SLC22A family. Antimicrob Agents Chemother 60:6558–6567.
29. Rodvold KA (1999) Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 37:385–398.
30. Rodvold KA and Neuhauser M (2001) Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 21:233S–252S.
31. Sato T, Yamaguchi H, Kogawa T, Abe T, and Mano N (2014) Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver. J Pharm Pharm Sci 17:475–484.
32. Sato T, Ito H, Hirata A, Abe T, Mano N, and Yamaguchi H (2017) Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3. Xenobiotica DOI: 10.1080/00498254.2016.1275880 [published ahead of print].
33. Schmitt C, Kaeser B, Riek M, Bech N, and Kreuzer C (2010) Effect of saquinavir/ ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. Int J Clin Pharmacol Ther 48:192–199.
34. Scotcher D, Jones CR, Galetin A, and Rostami-Hodjegan A (2017) Delineating the role of various factors in renal disposition of digoxin through application of physiologically based kidney model to renal impairment populations. J Pharmacol Exp Ther 360:484–495.
35. Scripture CD and Pieper JA (2001) Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 40:263–281.
36. Suga T, Yamaguchi H, Sato T, Maekawa M, Goto J, and Mano N (2017) Preference of conjugated bile acids over unconjugated bile acids as substrates for OATP1B1 and OATP1B3. PLoS One 12:e0169719.
37. Toyohara T, Suzuki T, Morimoto R, Akiyama Y, Souma T, Shiwaku HO, Takeuchi Y, Mishima E, Abe M, Tanemoto M, et al. (2009) SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol 20:2546–2555.
38. Vermeer LM, Isringhausen CD, Ogilvie BW, and Buckley DB (2016) Evaluation of ketoconazole and its alternative clinical CYP3A4/5 inhibitors as inhibitors of drug transporters: the in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters. Drug Metab Dispos 44: 453–459.
39. Viani A, Carrai M, and Pacifici GM (1989) Plasma protein binding of frusemide in liver disease: effect of hypoalbuminaemia and hyperbilirubinaemia. Br J Clin Pharmacol 28:175–178.
40. Vree TB, van den Biggelaar-Martea M, and Verwey-van Wissen CP (1995) Pro-benecid inhibits the renal clearance of frusemide and its acyl glucuronide. Br J Clin Pharmacol 39:692–695.
41. Yamaguchi H, Sugie M, Okada M, Mikkaichi T, Toyohara T, Abe T, Goto J, Hishinuma T, Shimada M, and Mano N (2010) Transport of estrone 3-sulfate mediated by organic anion transporter OATP4C1: estrone 3-sulfate binds to the different recognition site for digoxin in OATP4C1. Drug Metab Pharmacokinet 25:314–317.
42. Yang CH, Glover KP, and Han X (2009) Organic anion transporting polypeptide (Oatp) 1a1-mediated perfluorooctanoate transport and evidence for a renal reabsorption mechanism of Oatp1a1 in renal elimination of perfluorocarboxylates in rats. Toxicol Lett 190:163–171.
43. Yonezawa A and Inui K (2011) Organic cation transporter OCT/SLC22A and H(1)/ organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol 81:563–568.